Today: 5 February 2026
Subscribe
Browse Category

NYSE:MOS News 12 December 2025 - 17 December 2025

Mosaic Stock (NYSE: MOS) Slides on Brazil Phosphate Curtailments, Belarus Potash Sanctions Shift, and a Saskatchewan Mine Incident

Mosaic Stock (NYSE: MOS) Slides on Brazil Phosphate Curtailments, Belarus Potash Sanctions Shift, and a Saskatchewan Mine Incident

December 17, 2025 — The Mosaic Company (NYSE: MOS) is having one of those “three headlines collide at once” weeks: a sudden raw-material cost shock in Brazil, fresh geopolitical supply uncertainty in the potash market, and a serious safety incident at a key Canadian mine site. The stock is trading around $23.46, down about 5.6% from the previous close, after…
17 December 2025
····
Mosaic Company Stock (MOS) News Today: Supply Shock, Analyst Targets, and the 2026 Fertilizer Outlook (Dec. 12, 2025)

Mosaic Company Stock (MOS) News Today: Supply Shock, Analyst Targets, and the 2026 Fertilizer Outlook (Dec. 12, 2025)

The Mosaic Company (NYSE: MOS) is moving sharply in December 2025. Here’s the latest MOS stock news, analyst price targets, earnings outlook, dividend details, and key risks for 2026. Mosaic stock price today: MOS jumps as fertilizer headlines hit the tape The Mosaic Company’s stock (NYSE: MOS ) was trading around $26.10 on Friday, December 12, 2025 , up about…
12 December 2025
····

Stock Market Today

  • Boston Scientific Shares Dive 17.5% on Disappointing 2026 Profit Guidance
    February 4, 2026, 6:32 PM EST. Boston Scientific's stock plunged 17.5% to $75.59 on Feb. 4 after its Q4 earnings beat estimates but cautious 2026 profit guidance disappointed investors. The medical-device maker delivered 16% sales growth and 14% adjusted EPS growth in Q4, outperforming Wall Street expectations. However, weak guidance for the first quarter and 2026 EPS trimmed investor optimism, with EPS projections falling slightly short. Trading volume surged 581% above its three-month average, reflecting the sharp selloff. Despite the setback, Boston Scientific's Cardiovascular segment grew sales 18%, MedSurg unit revenues rose 12%, and management forecasted $4.2 billion in free cash flow for 2026. The decline was company-specific; peers Medtronic and Stryker showed smaller losses. Investors weigh today's reaction as overdone given Boston Scientific's consistent long-term growth and double-digit sales gains across 12 quarters.
Go toTop